Speech-Language Pathologists in Lighthouse Point, FL Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Janet Grote, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4821 Ne 27th Ter, Lighthouse Point, FL 33064 Phone: 954-420-9097

Able Therapy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3840 Ne 22nd Way, Lighthouse Point, FL 33064 Phone: 954-895-0532

Mrs. Lindsay Leeds Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 3126 N Federal Hwy, Lighthouse Point, FL 33064 Phone: 954-785-0900

Julia Rosin, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3840 Ne 22nd Way, Lighthouse Point, FL 33064 Phone: 954-895-0532

Mr. Sherri Ann Antoine, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2601 Ne 27th St, Lighthouse Point, FL 33064 Phone: 412-445-0884

Kelly Elizabeth Yount, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2301 Ne 36th St, Apartment 207, Lighthouse Point, FL 33064 Phone: 954-913-8776

News Archive

Blueberry compounds might aid in building strong bones

Compounds in blueberries might turn out to have a powerful effect on formation of strong, healthy bones, if results from studies with laboratory rats turn out to hold true for humans.

Bird flu vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded two contracts to support the production and clinical testing of an investigational vaccine based on a strain of avian influenza, H5N1, which might have the potential to cause pandemic influenza.

RIDEA joint-venture with Bickford acquires $135M for 17 assisted living, memory care communities

National Health Investors, Inc. (NYSE:NHI) announced today that its RIDEA joint-venture with Bickford Senior Living ("Bickford") has acquired 17 assisted living and memory care communities for a total purchase price of $135 million. NHI owns 85% of the joint-venture and Bickford owns 15%. The

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

Read more Medical News

› Verified 1 days ago